FDA's New Requirement for UniQure Gene Therapy Trial Sparks Ethical Debate

The U.S. Food and Drug Administration (FDA) has introduced a new requirement in a clinical trial for UniQure's innovative gene therapy, prompting ethical concerns. Bloomberg posted on X, highlighting the implications of this demand on the trial's progress and ethical considerations. The requirement involves additional safety measures, which some experts argue could delay the trial and impact patient access to potentially life-saving treatments. The debate centers around balancing patient safety with the urgency of advancing medical research. UniQure is navigating these challenges as it seeks to comply with the FDA's guidelines while addressing the ethical questions raised by this new demand.